Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HC-1119 |
Synonyms | |
Therapy Description |
HC-1119 is a deuterated version of enzalutamide that inhibits androgen receptor (AR) by blocking its nuclear translocation and DNA-binding activity, which potentially results in enhanced apoptosis and reduced growth of AR expressing tumor cells (Journal of Clinical Oncology 2018 36:15_suppl, e17021; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HC-1119 | HC 1119|HC1119|D3-ENT|Deuterated Enzalutamide|N-trideuteromethyl Enzalutamide | Hormone - Anti-androgens 54 | HC-1119 is a deuterated version of enzalutamide that inhibits androgen receptor (AR) by blocking its nuclear translocation and DNA-binding activity, which potentially results in enhanced apoptosis and reduced growth of AR expressing tumor cells (Journal of Clinical Oncology 2018 36:15_suppl, e17021; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03850795 | Phase III | Enzalutamide HC-1119 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Terminated | USA | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | AUS | 1 |